Philip Morris International Presents at 2024 CAGNY Conference; Reaffirms 2024 Full-Year Forecast for Reported Diluted EPS of $5.90 to $6.02 and Adjusted Diluted EPS of $6.32 to $6.44, Representing Currency-Neutral Growth of 7% to 9%

Regulatory News:

 Philip Morris International Inc.’s (PMI) (NYSE: PM) Chief Executive Officer, Jacek Olczak and Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2024 Consumer Analyst Group of New York (CAGNY) Conference.

The event will be webcast live in listen-only mode, beginning at approximately 10:00 a.m. ET, at and on the PMI Investor Relations Mobile Application ( Presentation slides will also be available on the same site and the App. An archived copy of the webcast will be available until Friday, March 22, 2024.

The presentation will cover:

  • PMI’s progress to date on becoming a substantially smoke-free business by 2030;
  • the science demonstrating why smoke-free products are a much better alternative;
  • PMI’s responsible marketing practices;
  • the success of company’s strong multi-category portfolio with leading premium brands in heat-not-burn and oral nicotine;
  • the first anniversary of our successful combination with Swedish Match, including progress on integration and a planned strategic review of the U.S. cigar business;
  • the financial model underlying the company’s smoke-free transformation; and the company’s strong financial and non-financial performance.

2024 Full-Year Forecast

PMI reaffirms its 2024 full-year reported diluted EPS forecast, announced on February 8th, of $5.90 to $6.02. Excluding a total 2024 adjustment of $0.42 per share and an unfavorable currency impact, at currently prevailing exchange rates, of $0.11 per share, this forecast represents a projected currency-neutral increase of 7% to 9% versus adjusted diluted EPS of $6.01 in 2023, as outlined in the below table.



















Reported Diluted EPS





$ 5.02















Asset impairment and exit costs







Termination of distribution arrangement in the Middle East







Income tax impact associated with Swedish Match AB financing







Amortization of intangibles








Impairment of goodwill and other intangibles







Charges related to the war in Ukraine







Swedish Match AB acquisition accounting related item







Termination of agreement with Foundation for a Smoke-Free World







South Korea indirect tax charge







Fair value adj. for equity security investments







Tax items (1)







Total Adjustments








Adjusted Diluted EPS





$ 6.01





Less: Currency








Adjusted Diluted EPS, excluding currency





$ 6.01





(1) 2023 Tax items relate to the unilateral suspension of certain Russian double tax treaties by the Russian government

The assumptions underlying this forecast remain unchanged versus those communicated by PMI in its earnings release of February 8, 2024.

Factors described in the Forward-Looking and Cautionary Statements section of this release represent continuing risks to these projections.

Forward-Looking & Cautionary Statements

The presentation, related discussion and this press release contain projections of future results and goals and other forward-looking statements, including statements regarding business plans and strategies. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI.

PMI's business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; the impact and consequences of Russia's invasion of Ukraine; changes in adult smoker behavior; the impact of COVID-19 on PMI's business; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of its information systems and effectiveness of its data privacy policies. PMI's future profitability may also be adversely affected should it be unsuccessful in its attempts to produce and commercialize reduced-risk products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity, enter new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the development of strategic business relationships; if it is unable to attract and retain the best global talent, including women or diverse candidates; or if it is unable to successfully integrate and realize the expected benefits from recent transactions and acquisitions. Future results are also subject to the lower predictability of our reduced-risk product category's performance.

PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2023. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested $12.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration has authorized versions of PMI’s IQOS Platform 1 devices and consumables and Swedish Match’s General snus as Modified Risk Tobacco Products. As of December 31, 2023, PMI's smoke-free products were available for sale in 84 markets, and PMI estimates that approximately 20.8 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products accounted for approximately 37% of PMI’s total full-year 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit and


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.